Spyre Therapeutics earnings were -$214.9M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest SYRE earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$69.0M, up 77.7% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, SYRE reported annual earnings of -$338.8M, with 304.2% growth.
What were Spyre Therapeutics's earnings last quarter?
On SYRE's earnings call on Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q3 2024 earnings per share (EPS) of -$1.06, up 23.26% year over year. Total SYRE earnings for the quarter were -$69.03 million. In the same quarter last year, Spyre Therapeutics's earnings per share (EPS) was -$0.86.
As of the last Spyre Therapeutics earnings report, Spyre Therapeutics is currently losing money. Spyre Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$214.90 million, a 27.01% decrease year over year.
What was SYRE's earnings growth in the past year?
As of Spyre Therapeutics's earnings date in Invalid Date, Spyre Therapeutics's earnings has grown year over year. SYRE earnings in the past year totalled -$214.90 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.